1. Ohio Administrative Rule 4729-5-19 was changed on January 1, 2011 to mandate that after the initial refills authorized are used, a new prescription must be written and a new prescription number must be assigned to any additional refills authorized by the prescriber.
   a. True
   b. False

2. When communicating prescription information to a pharmacy, a Drug Enforcement Administration (DEA) policy statement issued October 6, 2010 in the Federal Register states that a prescriber’s authorized agent may:
   a. Prepare the prescription, based on the instructions of the prescribing practitioner, for the signature of that DEA-registered practitioner.
   b. Transmit a practitioner-signed Schedule III - V prescription to a pharmacy via facsimile, or may communicate the prescription orally to a pharmacy on behalf of the practitioner.
   c. Transmit by facsimile a practitioner-signed Schedule II prescription for a patient in a hospice or long-term care facility on behalf of the practitioner.
   d. Be designated as that prescriber’s agent in writing.
   e. All of the above

3. As part of its Safe Use Initiative, the Food and Drug Administration encourages pharmacies to stop using the drug name acetaminophen and only use the abbreviation APAP since the abbreviation APAP is so common.
   a. True
   b. False

4. Out of the required 6.0 CEUs (60 hours) of continuing pharmacy education credit due every three years, at least _____ must be Ohio Board approved jurisprudence.
   a. 4.5 CEUs
   b. 20 hours
   c. 0.3 CEUs
   d. 0.1 CEUs
   e. None of the above

5. The “one transfer rule” that became effective January 1, 2011 was reversed by the Board and the reversal became effective in June 2011. This returned the rule to its previous language.
   a. True
   b. False

6. A pharmacist’s corresponding responsibility when filling prescriptions has become more important now than ever before. The impact of “pill mills” on the drug abuse problem in Ohio has resulted in the passage of HB 93 requiring:
   a. Pain management clinics to be licensed as Terminal Distributors with the Board of Pharmacy regardless of possessing drugs in the office or not.
   b. The pain management clinics to be owned only by one or more physicians.
   c. The owner or owners to have criminal background checks, but not their employees.
   d. Any Controlled Substances personally furnished by the physician are limited to a 72 hour supply of the medication and are exempt from reporting the furnishing of drugs to OARRS.
   e. a. and b. are correct.

7. With attention to a pharmacist’s corresponding responsibility when filling prescriptions, certain factors, among others, play a role in the decision process. These may include all except:
   a. Reviewing an OARRS report.
   b. Allowing the store’s regional supervisor to decide the legitimate medical purpose of a prescription before it is filled by the store’s pharmacist.
   c. Calling the prescriber for assurance alone may not be enough to assure legitimacy.
   d. The prescribing habits of the prescriber.
   e. The patient’s condition and dose of the drug or drugs prescribed.

8. The Food and Drug Administration is asking drug manufacturers to limit the strength of acetaminophen in prescription drug products to 325mg per tablet, capsule, or other dosage unit.
   a. True
   b. False
9. Common errors leading to inaccurate OARRS data include all of the following:
   a. Wrong prescriber identified by DEA number.
   b. Wrong date of birth entered.
   c. Entering date of dispensing instead of patient’s date of birth.
   d. Using the profile of a father or son with the same name that assigns the wrong date of birth.
   e. All of the above

10. One way to help minimize OARRS data errors is to review the pharmacy’s own prescription data when an OARRS report is requested on one of your patients. Contacting OARRS staff can help correct any problems noted.
   a. True
   b. False

11. When returning medications to stock (that have NOT been picked up by the patient) all are true except:
   a. The products returned to the shelf remain in the container in which they were dispensed and they retain their prescription label.
   b. There is, in the pharmacist’s professional judgment, a reasonable period of time left before the original manufacturer’s expiration date.
   c. There are a limited number of returned products on the stock shelves at any one time.
   d. The products are dispensed within a reasonable period of time and, if not, are removed from stock and properly destroyed.
   e. The contents of a prescription vial may be returned to the manufacturer’s stock bottle.

12. Recently the Food and Drug Administration issued a warning to consumers and health care workers regarding the use of benzocaine. Benzocaine has been associated with what rare, but serious, condition:
   a. Hepatic toxicity
   b. Renal calculi
   c. Methemoglobinemia
   d. Meralgia paresthetica
   e. Dystonia

13. Pradaxa® should only be dispensed and stored in the original bottle or blister package and once the product is opened the contents should be used within 6 months.
   a. True
   b. False

14. All of the following are true regarding HB 93 changes to rule 4729-5-20 – Prospective drug utilization review – except: An OARRS report should be obtained if a pharmacist becomes aware of
   a. A person receiving reported drugs from multiple prescribers.
   b. A person receiving reported drugs for more than twelve consecutive weeks.
   c. A person abusing or misusing reported drugs.
   d. A patient living greater than 3 miles from the pharmacy.
   e. The prescriber of reported drugs is located outside the usual pharmacy geographic prescriber care area.

15. If your pharmacy does not have internet access to allow obtaining an OARRS report on a patient, it is acceptable to document that fact in the patient profile to avoid any repercussions of the changes in rule 4729-5-20 regarding prospective drug utilization review.
   a. True
   b. False

16. Electronic prescribing of Controlled Substances is allowed if the prescribing and pharmacy systems have met the requirements set forth in the DEA rule published as an interim final rule on June 1, 2010. To meet this rule:
   a. A person qualified to conduct a SysTrust, WebTrust, or SAS 70 audit has approved the system.
   b. A Certified Information System Auditor who performs compliance audits as a regular ongoing business activity has approved the system.
   c. The DEA has approved the system.
   d. The National Association of Boards of Pharmacy has approved the system.
   e. Only a. and b. are correct.
## February 2012 Jurisprudence Quiz Answer Sheet

### JURISPRUDENCE REQUIREMENT FOR CPE

To receive a certificate of credit, please complete this form and mail it to the address below with a check for **$4.00** payable to Adherence Inc.

A certificate will be mailed to those receiving a passing score of 75 or better.

**JURISPRUDENCE CPE; ADHERENCE INC.; P. O. BOX 42407; CINCINNATI, OHIO 45242-0407**

**Program Evaluation:**

[1=Poor / 2=Fair / 3=Satisfactory / 4=Good / 5=Excellent]

(Please rate this program in the following areas)

- ♦ Quality of information 1 2 3 4 5
- ♦ Usefulness to my practice 1 2 3 4 5
- ♦ Readability and presentation 1 2 3 4 5

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>3.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>5.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>7.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>8.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>10.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>12.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>13.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
<tr>
<td>15.</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
</tr>
</tbody>
</table>

**NAME:** [PLEASE PRINT LEGIBLY OR TYPE]  
**OHIO PHARMACIST I.D. NUMBER:**

03 — —

**ADDRESS:**  
**DAYTIME TELEPHONE NUMBER:**

CITY:  
**STATE:**

ZIP CODE:

Mail this answer sheet to:

**ADHERENCE INC.; P. O. BOX 42407; CINCINNATI, OHIO 45242-0407**

(513/794-1642)

No credit can be granted for Answer Sheets postmarked after March 31, 2012.